Clearant to Hold Conference Call to Announce New Growth Strategies on May 9 at 11 a.m. ET; Call to Include Market Commentary by Two Renowned Orthopedic Surgeons.

LOS ANGELES -- Clearant, Inc. (OTCBB:CLRI) today announced that the Company will host an investment-community conference call, including slide presentation, in connection with the launch of its new sales and marketing strategy. The call is scheduled for Tuesday, May 9, 2006, beginning at 11:00 a.m. Eastern time (8:00 a.m. Pacific time) and will include the participation of two renowned orthopedic surgeons who will address the significant new market opportunities for Clearant, and the benefits and growing need for tissue sterilized with the CLEARANT PROCESS.

The conference call will feature Clearant management discussing the Company's new growth strategies to address larger market opportunities, as well as 2006 operational milestones that the Company expects to achieve during the transition to its new business model. Speakers on the call will include:

--Alain Delongchamp, chief executive officer of Clearant

--Fred D. Cushner, M.D., chairman of Orthopedics Division, Kingsbrook Jewish Medical Center (Brooklyn, N.Y.); director, Insall Scott Kelly Institute (New York, N.Y.); and former team orthopedic surgeon for the New York Knicks

--Ronald A. Navarro, M.D., chief of Ortho Services, Orthopedic Surgery, Kaiser Permanente South Bay Medical Center (Harbor City, Calif.), and affiliated physician for the Chicago Wolves ice hockey team.

Individuals interested in listening to the live conference call may do so by dialing [phone] toll free within the U.S. and Canada, or [phone] for international callers. To access the slide presentation, please visit the "Investors" section of the Company's Web site at www.clearant.com. A telephone replay of the conference call will be available for 48 hours beginning May 9 within two hours after the conclusion of the call, by dialing [phone] domestically or [phone] internationally, and entering reservation number 8664783.

Individuals interested in listening to the conference call via the Internet may do so by visiting www.clearant.com. A replay will be available on the Company's Web site for 30 days.

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected CLEARANT PROCESS, which substantially reduces all types of pathogens in biological products while maintaining a high degree of the underlying protein. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the CLEARANT PROCESS reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the CLEARANT PROCESS can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.